Symbols / ABVC $1.39 +26.36% ABVC BioPharma, Inc.
ABVC Chart
About
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 35.64M |
| Enterprise Value | 31.85M | Income | -7.91M | Sales | — |
| Book/sh | 0.46 | Cash/sh | 0.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 16 | IPO | — |
| P/E | — | Forward P/E | -3.16 | PEG | — |
| P/S | — | P/B | 3.04 | P/C | — |
| EV/EBITDA | -4.47 | EV/Sales | — | Quick Ratio | 0.12 |
| Current Ratio | 0.41 | Debt/Eq | 26.12 | LT Debt/Eq | — |
| EPS (ttm) | -0.39 | EPS next Y | -0.44 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-05-15 16:00 | ROA | -31.25% |
| ROE | -119.49% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 3.76% | Profit Margin | 0.00% | Shs Outstand | 25.64M |
| Shs Float | 19.88M | Short Float | 1.20% | Short Ratio | 4.53 |
| Short Interest | — | 52W High | 5.48 | 52W Low | 0.73 |
| Beta | 0.38 | Avg Volume | 57.39K | Volume | 563.26K |
| Target Price | — | Recom | None | Prev Close | $1.10 |
| Price | $1.39 | Change | 26.36% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- 12 Health Care Stocks Moving In Monday's Intraday Session - ABVC BioPharma (NASDAQ:ABVC), Aditxt (NASDAQ - Benzinga Mon, 06 Apr 2026 17
- ABVC BioPharma Surges 22.9% Intraday: What’s Fueling This Volatile Move? - Bitget Mon, 06 Apr 2026 15
- ABVC,TSLA,RHHBF,PVH,LAZ,GMAB,JNJ,MRK,PFE | stock prices | quote comparison - Yahoo Finance UK Fri, 03 Apr 2026 18
- ABVC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI Wed, 01 Apr 2026 09
- ABVC BioPharma (ABVC) investors re-elect board and approve 2026 plan - Stock Titan Fri, 27 Mar 2026 07
- ABVC: ABVC BIOPHARMA - Interactive Chart - Zacks Investment Research Sat, 04 Apr 2026 17
- ABVC BioPharma Shareholders Back Board, Equity Plan Changes - TipRanks Fri, 27 Mar 2026 07
- ABVC BioPharma shareholders approve director slate and equity plan at annual meeting - investing.com Fri, 27 Mar 2026 07
- AirSculpt Technologies, Inc. - Common Stock (NQ: AIRS - The Chronicle-Journal hu, 02 Apr 2026 20
- ABVC 10-Q & SEC Filings - sg.finance.yahoo.com Sun, 05 Apr 2026 00
- 12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga Mon, 30 Mar 2026 21
- ABVC Surges Post-Market on Trial News, But Volume Tells a Cautious Story - Bitget Mon, 30 Mar 2026 06
- ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies - Yahoo Finance ue, 23 Sep 2025 07
- ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Yahoo Finance Mon, 03 Nov 2025 08
- ABVC BioPharma’s Bold $1 Billion Valuation Bet: Insiders Remain on the Sidelines Amid Pending Incentive - Bitget Fri, 27 Mar 2026 13
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
0.51
+234.31%
|
0.15
-84.28%
|
0.97
|
| Operating Revenue |
|
0.00
-100.00%
|
0.51
+234.31%
|
0.15
-84.28%
|
0.97
|
| Cost Of Revenue |
|
0.00
-100.00%
|
0.00
-99.75%
|
0.30
+5.45%
|
0.29
|
| Reconciled Cost Of Revenue |
|
0.00
-100.00%
|
0.00
-99.75%
|
0.30
+5.45%
|
0.29
|
| Gross Profit |
|
0.00
-100.00%
|
0.51
+440.11%
|
-0.15
-121.89%
|
0.68
|
| Operating Expense |
|
7.15
+37.15%
|
5.21
-21.20%
|
6.62
-58.11%
|
15.80
|
| Research And Development |
|
0.12
-32.46%
|
0.18
-83.13%
|
1.06
-60.54%
|
2.69
|
| Selling General And Administration |
|
7.03
+39.63%
|
5.03
-9.35%
|
5.55
-57.62%
|
13.10
|
| General And Administrative Expense |
|
7.03
+39.63%
|
5.03
-9.35%
|
5.55
-57.62%
|
13.10
|
| Salaries And Wages |
|
4.14
+49.37%
|
2.77
+1391.64%
|
0.19
-97.36%
|
7.04
|
| Other Gand A |
|
2.89
+27.68%
|
2.26
-57.88%
|
5.37
-11.52%
|
6.07
|
| Other Operating Expenses |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
7.15
+37.13%
|
5.21
-24.63%
|
6.92
-56.98%
|
16.08
|
| Operating Income |
|
-7.15
-51.98%
|
-4.71
+30.47%
|
-6.77
+55.23%
|
-15.11
|
| Total Operating Income As Reported |
|
-7.15
-51.98%
|
-4.71
+30.47%
|
-6.77
+55.23%
|
-15.11
|
| EBITDA |
|
-7.43
-71.14%
|
-4.34
+31.40%
|
-6.33
+58.34%
|
-15.20
|
| Normalized EBITDA |
|
-6.36
-50.18%
|
-4.23
+30.95%
|
-6.13
+58.63%
|
-14.82
|
| Reconciled Depreciation |
|
0.50
+151.26%
|
0.20
-47.18%
|
0.38
+1498.34%
|
0.02
|
| EBIT |
|
-7.94
-74.68%
|
-4.54
+32.30%
|
-6.71
+55.91%
|
-15.22
|
| Total Unusual Items |
|
-1.07
-887.28%
|
-0.11
+45.42%
|
-0.20
+47.17%
|
-0.38
|
| Total Unusual Items Excluding Goodwill |
|
-1.07
-887.28%
|
-0.11
+45.42%
|
-0.20
+47.17%
|
-0.38
|
| Special Income Charges |
|
-0.80
-414.18%
|
0.26
|
0.00
+100.00%
|
-0.11
|
| Other Special Charges |
|
—
|
-0.26
|
—
|
—
|
| Write Off |
|
0.80
|
0.00
|
0.00
-100.00%
|
0.11
|
| Net Income |
|
-7.91
-61.30%
|
-4.90
+37.05%
|
-7.79
+52.58%
|
-16.42
|
| Pretax Income |
|
-8.35
-55.56%
|
-5.37
+33.09%
|
-8.02
+48.28%
|
-15.51
|
| Net Non Operating Interest Income Expense |
|
-0.25
+66.31%
|
-0.74
+34.54%
|
-1.13
-962.82%
|
-0.11
|
| Interest Expense Non Operating |
|
0.42
-49.64%
|
0.83
-37.13%
|
1.31
+346.88%
|
0.29
|
| Net Interest Income |
|
-0.25
+66.31%
|
-0.74
+34.54%
|
-1.13
-962.82%
|
-0.11
|
| Interest Expense |
|
0.42
-49.64%
|
0.83
-37.13%
|
1.31
+346.88%
|
0.29
|
| Interest Income Non Operating |
|
0.17
+91.29%
|
0.09
-52.90%
|
0.19
-1.24%
|
0.19
|
| Interest Income |
|
0.17
+91.29%
|
0.09
-52.90%
|
0.19
-1.24%
|
0.19
|
| Other Income Expense |
|
-0.95
-1383.92%
|
0.07
+157.12%
|
-0.13
+55.82%
|
-0.29
|
| Other Non Operating Income Expenses |
|
0.12
-34.10%
|
0.18
+164.02%
|
0.07
-16.53%
|
0.08
|
| Gain On Sale Of Security |
|
-0.27
+25.80%
|
-0.36
-82.89%
|
-0.20
+25.37%
|
-0.27
|
| Tax Provision |
|
0.02
+121.85%
|
-0.11
-143.18%
|
0.26
-67.91%
|
0.80
|
| Tax Rate For Calcs |
|
0.00
+920.11%
|
0.00
-90.20%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.23
-9971.28%
|
-0.00
+94.65%
|
-0.04
+47.17%
|
-0.08
|
| Net Income Including Noncontrolling Interests |
|
-8.38
-59.29%
|
-5.26
+36.49%
|
-8.28
+49.24%
|
-16.31
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.91
-61.30%
|
-4.90
+37.05%
|
-7.79
+52.58%
|
-16.42
|
| Net Income From Continuing And Discontinued Operation |
|
-7.91
-61.30%
|
-4.90
+37.05%
|
-7.79
+52.58%
|
-16.42
|
| Net Income Continuous Operations |
|
-8.38
-59.29%
|
-5.26
+36.49%
|
-8.28
+49.24%
|
-16.31
|
| Minority Interests |
|
0.47
+31.52%
|
0.36
-27.73%
|
0.49
+544.50%
|
-0.11
|
| Normalized Income |
|
-7.06
-47.21%
|
-4.80
+37.14%
|
-7.63
+52.68%
|
-16.13
|
| Net Income Common Stockholders |
|
-7.91
-61.30%
|
-4.90
+37.05%
|
-7.79
+52.58%
|
-16.42
|
| Diluted EPS |
|
—
|
-0.42
+76.67%
|
-1.80
+65.38%
|
-5.20
|
| Basic EPS |
|
—
|
-0.42
+76.67%
|
-1.80
+65.38%
|
-5.20
|
| Basic Average Shares |
|
—
|
11.67
+169.26%
|
4.34
+36.92%
|
3.17
|
| Diluted Average Shares |
|
—
|
11.67
+169.26%
|
4.34
+36.92%
|
3.17
|
| Diluted NI Availto Com Stockholders |
|
-7.91
-61.30%
|
-4.90
+37.05%
|
-7.79
+52.58%
|
-16.42
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
21.06
+179.34%
|
7.54
-3.14%
|
7.78
-18.74%
|
9.58
|
| Current Assets |
|
2.50
+14.75%
|
2.18
+31.58%
|
1.66
-44.54%
|
2.99
|
| Cash Cash Equivalents And Short Term Investments |
|
0.75
+138.20%
|
0.31
+124.51%
|
0.14
-13.41%
|
0.16
|
| Cash And Cash Equivalents |
|
0.68
+174.37%
|
0.25
+312.90%
|
0.06
-29.45%
|
0.09
|
| Other Short Term Investments |
|
0.06
-0.59%
|
0.06
-18.38%
|
0.08
+4.64%
|
0.08
|
| Receivables |
|
0.76
-33.91%
|
1.16
+52.07%
|
0.76
-44.54%
|
1.37
|
| Accounts Receivable |
|
—
|
0.00
-100.00%
|
0.00
-98.44%
|
0.10
|
| Gross Accounts Receivable |
|
—
|
0.62
-0.26%
|
0.62
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
-0.62
+0.01%
|
-0.62
|
—
|
| Inventory |
|
—
|
—
|
—
|
0.00
|
| Raw Materials |
|
—
|
—
|
—
|
0.00
|
| Work In Process |
|
—
|
—
|
—
|
0.00
|
| Finished Goods |
|
—
|
—
|
—
|
0.00
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.65
+4.89%
|
0.62
-6.27%
|
0.66
-49.74%
|
1.31
|
| Other Current Assets |
|
0.35
+260.26%
|
0.10
-4.79%
|
0.10
-32.74%
|
0.15
|
| Total Non Current Assets |
|
18.56
+246.28%
|
5.36
-12.53%
|
6.13
-7.05%
|
6.59
|
| Net PPE |
|
14.75
+1180.85%
|
1.15
-16.47%
|
1.38
-20.55%
|
1.74
|
| Gross PPE |
|
18.13
+303.47%
|
4.49
-4.68%
|
4.71
-6.47%
|
5.04
|
| Accumulated Depreciation |
|
-3.38
-1.15%
|
-3.34
-0.20%
|
-3.34
-0.93%
|
-3.30
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
12.69
+3642.46%
|
0.34
-6.73%
|
0.36
+0.62%
|
0.36
|
| Buildings And Improvements |
|
2.22
+0.22%
|
2.22
-0.37%
|
2.23
+0.03%
|
2.23
|
| Machinery Furniture Equipment |
|
1.31
+0.86%
|
1.29
-1.44%
|
1.31
+1.78%
|
1.29
|
| Construction In Progress |
|
—
|
—
|
7.40
|
0.00
|
| Other Properties |
|
1.91
+198.77%
|
0.64
-20.87%
|
0.81
-30.30%
|
1.16
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Goodwill |
|
—
|
—
|
—
|
—
|
| Investments And Advances |
|
1.88
-16.84%
|
2.26
-10.64%
|
2.53
+200.18%
|
0.84
|
| Long Term Equity Investment |
|
1.85
+25.96%
|
1.47
-12.61%
|
1.68
|
0.00
|
| Other Investments |
|
—
|
—
|
0.85
+0.62%
|
0.84
|
| Non Current Accounts Receivable |
|
—
|
—
|
0.11
-86.88%
|
0.87
|
| Non Current Deferred Assets |
|
—
|
—
|
0.00
-100.00%
|
0.12
|
| Non Current Deferred Taxes Assets |
|
—
|
—
|
0.00
-100.00%
|
0.12
|
| Non Current Prepaid Assets |
|
1.82
+0.00%
|
1.82
-7.63%
|
1.97
-35.15%
|
3.03
|
| Other Non Current Assets |
|
0.12
-12.14%
|
0.13
-5.74%
|
0.14
|
—
|
| Total Liabilities Net Minority Interest |
|
7.76
+13.92%
|
6.82
+4.36%
|
6.53
+2.96%
|
6.34
|
| Current Liabilities |
|
6.16
-6.00%
|
6.56
+7.47%
|
6.10
+10.07%
|
5.54
|
| Payables And Accrued Expenses |
|
2.36
-12.45%
|
2.70
+14.42%
|
2.36
+5.71%
|
2.23
|
| Payables |
|
0.12
-84.78%
|
0.77
+169.88%
|
0.29
-20.43%
|
0.36
|
| Accounts Payable |
|
—
|
—
|
—
|
—
|
| Current Accrued Expenses |
|
2.25
+16.56%
|
1.93
-7.05%
|
2.07
+10.74%
|
1.87
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.45
+25.44%
|
1.15
+9.99%
|
1.05
+84.12%
|
0.57
|
| Total Tax Payable |
|
0.01
|
0.00
-100.00%
|
0.11
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
1.87
-14.67%
|
2.19
+0.29%
|
2.19
-3.33%
|
2.26
|
| Current Debt |
|
1.55
-13.17%
|
1.79
+0.25%
|
1.79
-5.70%
|
1.89
|
| Other Current Borrowings |
|
0.80
-15.90%
|
0.95
+7.17%
|
0.89
|
—
|
| Current Capital Lease Obligation |
|
0.32
-21.32%
|
0.40
+0.44%
|
0.40
+8.80%
|
0.37
|
| Current Deferred Liabilities |
|
0.01
-84.47%
|
0.08
+2.03%
|
0.08
+623.71%
|
0.01
|
| Current Deferred Revenue |
|
0.01
-84.47%
|
0.08
+2.03%
|
0.08
+623.71%
|
0.01
|
| Other Current Liabilities |
|
0.47
+9.31%
|
0.43
+0.65%
|
0.43
-8.72%
|
0.47
|
| Total Non Current Liabilities Net Minority Interest |
|
1.60
+519.28%
|
0.26
-39.77%
|
0.43
-46.34%
|
0.80
|
| Long Term Debt And Capital Lease Obligation |
|
1.60
+575.97%
|
0.24
-41.88%
|
0.41
-48.54%
|
0.79
|
| Long Term Capital Lease Obligation |
|
1.60
+575.97%
|
0.24
-41.88%
|
0.41
-48.54%
|
0.79
|
| Other Non Current Liabilities |
|
—
|
0.02
+0.00%
|
0.02
+171.71%
|
0.01
|
| Stockholders Equity |
|
11.11
+806.25%
|
1.23
-21.10%
|
1.55
-49.84%
|
3.10
|
| Common Stock Equity |
|
11.11
+806.25%
|
1.23
-21.10%
|
1.55
-49.84%
|
3.10
|
| Capital Stock |
|
0.03
+80.65%
|
0.01
+74.66%
|
0.01
+141.63%
|
0.00
|
| Common Stock |
|
0.03
+80.65%
|
0.01
+74.66%
|
0.01
+141.63%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
25.05
+80.65%
|
13.87
+74.66%
|
7.94
+139.65%
|
3.31
|
| Ordinary Shares Number |
|
24.32
+85.13%
|
13.14
+66.01%
|
7.91
+140.85%
|
3.29
|
| Treasury Shares Number |
|
0.73
+0.00%
|
0.73
+2651.63%
|
0.03
-3.56%
|
0.03
|
| Additional Paid In Capital |
|
96.01
+22.16%
|
78.60
+6.24%
|
73.98
+8.89%
|
67.94
|
| Retained Earnings |
|
-76.86
-11.47%
|
-68.95
-7.66%
|
-64.05
-16.65%
|
-54.90
|
| Gains Losses Not Affecting Retained Earnings |
|
0.49
+9.41%
|
0.45
-13.70%
|
0.52
-0.14%
|
0.52
|
| Treasury Stock |
|
8.91
+0.00%
|
8.91
+0.09%
|
8.90
-2.18%
|
9.10
|
| Minority Interest |
|
2.19
+535.23%
|
-0.50
-67.04%
|
-0.30
-318.56%
|
0.14
|
| Other Equity Adjustments |
|
0.49
+9.41%
|
0.45
-13.70%
|
0.52
-0.14%
|
0.52
|
| Total Equity Gross Minority Interest |
|
13.30
+1736.77%
|
0.72
-42.24%
|
1.25
-61.27%
|
3.24
|
| Total Capitalization |
|
11.11
+806.25%
|
1.23
-21.10%
|
1.55
-49.84%
|
3.10
|
| Working Capital |
|
-3.66
+16.33%
|
-4.38
+1.52%
|
-4.45
-73.89%
|
-2.56
|
| Invested Capital |
|
12.67
+319.91%
|
3.02
-9.68%
|
3.34
-33.10%
|
4.99
|
| Total Debt |
|
3.47
+42.87%
|
2.43
-6.33%
|
2.60
-15.05%
|
3.05
|
| Net Debt |
|
0.87
-43.38%
|
1.54
-10.65%
|
1.73
-4.58%
|
1.81
|
| Capital Lease Obligations |
|
1.92
+199.55%
|
0.64
-20.87%
|
0.81
-30.30%
|
1.16
|
| Net Tangible Assets |
|
11.11
+806.25%
|
1.23
-21.10%
|
1.55
-49.84%
|
3.10
|
| Tangible Book Value |
|
11.11
+806.25%
|
1.23
-21.10%
|
1.55
-49.84%
|
3.10
|
| Available For Sale Securities |
|
0.03
-96.36%
|
0.79
-6.73%
|
0.85
+0.62%
|
0.84
|
| Current Notes Payable |
|
0.03
+0.00%
|
0.03
|
0.00
|
—
|
| Duefrom Related Parties Current |
|
0.76
-33.91%
|
1.16
+52.37%
|
0.76
-40.37%
|
1.27
|
| Duefrom Related Parties Non Current |
|
—
|
0.00
-100.00%
|
0.11
-86.88%
|
0.87
|
| Dueto Related Parties Current |
|
0.11
-86.33%
|
0.77
+345.58%
|
0.17
-51.81%
|
0.36
|
| Inventories Adjustments Allowances |
|
—
|
—
|
—
|
0.00
|
| Investmentin Financial Assets |
|
0.03
-96.36%
|
0.79
-6.73%
|
0.85
+0.62%
|
0.84
|
| Investmentsin Associatesat Cost |
|
1.85
+25.96%
|
1.47
-12.61%
|
1.68
|
0.00
|
| Investmentsin Joint Venturesat Cost |
|
0.00
|
0.00
|
—
|
—
|
| Line Of Credit |
|
0.73
-10.46%
|
0.81
-9.90%
|
0.90
-52.51%
|
1.89
|
| Other Equity Interest |
|
0.36
+1056.57%
|
0.03
+106.88%
|
-0.45
+66.67%
|
-1.35
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-2.99
-65.07%
|
-1.81
+56.79%
|
-4.19
+43.41%
|
-7.40
|
| Cash Flow From Continuing Operating Activities |
|
-2.99
-65.07%
|
-1.81
+56.79%
|
-4.19
+43.41%
|
-7.40
|
| Net Income From Continuing Operations |
|
-8.38
-59.29%
|
-5.26
+36.49%
|
-8.28
+49.24%
|
-16.31
|
| Depreciation Amortization Depletion |
|
0.50
+151.26%
|
0.20
-47.18%
|
0.38
+1498.34%
|
0.02
|
| Depreciation |
|
0.50
+151.26%
|
0.20
-47.18%
|
0.38
+1498.34%
|
0.02
|
| Depreciation And Amortization |
|
0.50
+151.26%
|
0.20
-47.18%
|
0.38
+1498.34%
|
0.02
|
| Other Non Cash Items |
|
0.35
-34.10%
|
0.53
-57.18%
|
1.24
+3746.20%
|
0.03
|
| Stock Based Compensation |
|
4.14
+49.37%
|
2.77
+1391.64%
|
0.19
-97.36%
|
7.04
|
| Provisionand Write Offof Assets |
|
0.00
-100.00%
|
0.01
-99.18%
|
1.46
+591.05%
|
0.21
|
| Asset Impairment Charge |
|
0.81
|
0.00
|
0.00
-100.00%
|
0.11
|
| Deferred Tax |
|
—
|
0.00
-100.00%
|
0.12
-86.62%
|
0.86
|
| Deferred Income Tax |
|
—
|
0.00
-100.00%
|
0.12
-86.62%
|
0.86
|
| Operating Gains Losses |
|
0.19
-43.17%
|
0.34
+52.86%
|
0.22
|
—
|
| Gain Loss On Investment Securities |
|
0.19
-43.17%
|
0.34
+52.86%
|
0.22
|
—
|
| Change In Working Capital |
|
-0.62
-50.65%
|
-0.41
-183.22%
|
0.49
-22.78%
|
0.64
|
| Change In Receivables |
|
-0.14
+53.57%
|
-0.29
-215.35%
|
-0.09
+93.58%
|
-1.45
|
| Changes In Account Receivables |
|
—
|
0.00
-100.00%
|
0.23
+137.21%
|
-0.61
|
| Change In Inventory |
|
-0.01
|
0.00
|
—
|
0.00
|
| Change In Prepaid Assets |
|
-0.07
-653.39%
|
0.01
-87.30%
|
0.10
-57.19%
|
0.24
|
| Change In Payables And Accrued Expense |
|
0.16
+311.73%
|
0.04
-94.70%
|
0.75
-59.39%
|
1.85
|
| Change In Accrued Expense |
|
0.15
-0.40%
|
0.15
-76.08%
|
0.64
-60.30%
|
1.61
|
| Change In Payable |
|
0.01
+110.59%
|
-0.11
-200.00%
|
0.11
-53.42%
|
0.24
|
| Change In Account Payable |
|
—
|
—
|
—
|
0.00
|
| Change In Other Working Capital |
|
-0.09
-5386.69%
|
0.00
-98.04%
|
0.08
+3262.12%
|
-0.00
|
| Change In Other Current Liabilities |
|
-0.47
-180.93%
|
-0.17
+52.00%
|
-0.35
-13433.04%
|
-0.00
|
| Investing Cash Flow |
|
-1.21
|
0.00
+100.00%
|
-0.36
+79.08%
|
-1.72
|
| Cash Flow From Continuing Investing Activities |
|
-1.21
|
0.00
+100.00%
|
-0.36
+79.08%
|
-1.72
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.02
+82.29%
|
-0.12
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.02
+82.29%
|
-0.12
|
| Capital Expenditure |
|
—
|
—
|
-0.02
+82.29%
|
-0.12
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Investment |
|
—
|
—
|
—
|
0.00
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.34
+78.84%
|
-1.60
|
| Purchase Of Business |
|
—
|
0.00
+100.00%
|
-0.34
+78.84%
|
-1.60
|
| Net Other Investing Changes |
|
-1.20
|
—
|
—
|
—
|
| Financing Cash Flow |
|
4.64
+134.15%
|
1.98
-48.82%
|
3.87
-3.59%
|
4.01
|
| Cash Flow From Continuing Financing Activities |
|
4.64
+134.15%
|
1.98
-48.82%
|
3.87
-3.59%
|
4.01
|
| Net Issuance Payments Of Debt |
|
0.34
+2043.20%
|
0.02
-96.56%
|
0.46
+32.18%
|
0.35
|
| Issuance Of Debt |
|
0.89
+138.92%
|
0.37
-74.56%
|
1.46
+317.89%
|
0.35
|
| Repayment Of Debt |
|
-0.55
-53.77%
|
-0.36
+64.38%
|
-1.00
|
0.00
|
| Long Term Debt Issuance |
|
0.39
+1200.00%
|
0.03
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-0.43
-30.66%
|
-0.33
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
-0.04
+87.45%
|
-0.30
|
0.00
|
0.00
|
| Short Term Debt Issuance |
|
0.50
+45.87%
|
0.34
-76.61%
|
1.46
+317.89%
|
0.35
|
| Short Term Debt Payments |
|
-0.12
-313.01%
|
-0.03
+97.08%
|
-1.00
|
0.00
|
| Net Short Term Debt Issuance |
|
0.38
+20.98%
|
0.31
-32.35%
|
0.46
+32.18%
|
0.35
|
| Net Common Stock Issuance |
|
3.31
+13834.67%
|
0.02
-97.74%
|
1.05
-71.34%
|
3.66
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.99
-26.10%
|
1.34
-44.25%
|
2.41
|
0.00
|
| Net Other Financing Charges |
|
—
|
0.60
+1323.60%
|
-0.05
|
—
|
| Changes In Cash |
|
0.44
+158.07%
|
0.17
+125.35%
|
-0.68
+86.74%
|
-5.11
|
| Effect Of Exchange Rate Changes |
|
0.02
+182.41%
|
-0.02
-1257.13%
|
0.00
+103.16%
|
-0.07
|
| Beginning Cash Position |
|
0.86
+20.51%
|
0.72
-48.50%
|
1.39
-78.80%
|
6.57
|
| End Cash Position |
|
1.33
+53.62%
|
0.86
+20.51%
|
0.72
-48.50%
|
1.39
|
| Free Cash Flow |
|
-2.99
-65.07%
|
-1.81
+57.01%
|
-4.21
+44.03%
|
-7.52
|
| Interest Paid Supplemental Data |
|
0.03
+39.84%
|
0.02
-32.07%
|
0.03
-88.38%
|
0.29
|
| Income Tax Paid Supplemental Data |
|
0.01
-53.30%
|
0.03
-5.58%
|
0.03
+1612.00%
|
0.00
|
| Change In Income Tax Payable |
|
0.01
+110.59%
|
-0.11
-200.00%
|
0.11
|
0.00
|
| Change In Interest Payable |
|
—
|
—
|
—
|
-0.00
|
| Change In Tax Payable |
|
0.01
+110.59%
|
-0.11
-200.00%
|
0.11
|
0.00
|
| Common Stock Issuance |
|
3.31
+10548.53%
|
0.03
-97.04%
|
1.05
-71.34%
|
3.66
|
| Issuance Of Capital Stock |
|
3.31
+10548.53%
|
0.03
-97.04%
|
1.05
-71.34%
|
3.66
|
| Net Investment Properties Purchase And Sale |
|
-0.01
|
0.00
|
—
|
—
|
| Purchase Of Investment Properties |
|
-0.01
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-27 View
- 10-K2026-03-03 View
- 8-K2026-03-03 View
- 8-K2025-11-03 View
- 10-Q2025-11-03 View
- 8-K2025-10-30 View
- 8-K2025-08-14 View
- 10-Q2025-08-13 View
- 8-K2025-06-04 View
- 8-K2025-05-01 View
- 10-Q2025-04-30 View
- 8-K2025-04-30 View
- 8-K2025-04-15 View
- 10-K2025-04-15 View
- 8-K2025-03-07 View
- 8-K2025-01-06 View
- 8-K2024-11-14 View
- 10-Q2024-11-14 View
- 8-K2024-11-04 View
- 8-K2024-10-18 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|